Royalty Report: Cancer, Drugs, Therapeutic – Collection: 29247

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 16

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 16

Primary Industries

  • Cancer
  • Drugs
  • Therapeutic
  • Biotechnology
  • Disease
  • Diagnostic
  • Medical
  • Device
  • Delivery
  • Pharmaceuticals
  • Vaccine
  • Drug Discovery
  • Central Nervous System
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29247

License Grant
The Licensor granted an exclusive license to the patent, Tumor Radiosensitization Using Gene Therapy, for the prevention and treatment of all cancers except colon cancer, brain tumors and melanoma.
Field of Use
'Field' shall mean the prevention and treatment of all cancers except colon cancer, brain tumors and melanoma.

IPSCIO Record ID: 26619

License Grant
The Licensor hereby grants to the Licensee and its Affiliates a sole and exclusive worldwide sublicense in all fields of use to practice under the Patent Rights and to utilize the Know-how, and to make, have made, use, lease and/or sell the Licensed Products and to practice the Licensed Processes, to the full end of the term for which the Patent Rights are granted, unless sooner terminated as hereinafter provided.
License Property
The Licensor desires to sublicense of such Patent Rights and Know-how in order to commercialize 06-Benzyl guanine (06BG) and related technologies for the treatment of cancer.

O6-Benzylguanine (O6-BG) is a chemosensitizer that is designed to overcome resistance to a significant class of commonly used chemotherapeutic agents known as O6-alkylating agents.  In preclinical animal studies, treatment with O6-BG increased the anti-tumor activity of these agents in brain, colon, and prostate cancers, as well as in melanoma.   A Phase II development program began in 1999.  O6-BG, a series of related compounds and a gene therapy that the Company believes will enhance the effectiveness of a class of currently used chemotherapeutic agents known as O6-alkylating agents.  O6-BG and related compounds are small molecules for intravenous administration in the treatment of cancer.  The Company believes O6-BG to be capable of destroying the resistance of cancer cells to a class of chemotherapeutic agents, O6-alkylating agents.  The Company believes that the effectiveness of alkylating chemotherapeutic agents against various tumors such as brain, prostate, colon cancers, melanoma and lymphoma is limited due to the ability of tumor cells to repair the DNA damage caused by the O6-alkylating agents, because the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT), protects tumor cells by repairing the tumor cell DNA.

The Company believes that O6-BG inactivates the AGT protein in a variety of cancers thereby overcoming resistance to theO6-alkylating agents.

Field of Use
The rights granted apply in all fields of use relating to technologies for the treatment of cancer.

IPSCIO Record ID: 26852

License Grant
Licensor hereby grants to Licensee an exclusive license (with the right to grant sublicenses) under the Licensed Patent Rights, in jurisdictions where Licensed Patent Rights exist, to (a)  make, have made and use Licensed Products in the Field, (b) to sell and offer to sell Licensed Products for use in the Field, and (c) to practice Licensed Methods in the Field.
License Property
The license relates to U.S. patent application for the use of tumor radio sensitization using gene therapy.  Entitled Tumor Radiosensitization Using Gene Therapy.
Field of Use
Field shall mean the prevention and treatment of tumors of the urogenital system, excluding the ovaries, in humans.

IPSCIO Record ID: 1370

License Grant
The Company acquired exclusive worldwide rights to the GliaSite® Radiation Therapy System.

Licensor is willing to grant Licensee rights to the Licensor IP in the Territory with a limited field of use of intracavity radiation therapy (brachytherapy) of the brain (“Exclusive Field of Use”).

License Property
the GliaSite® Radiation Therapy System, the only FDA-cleared balloon catheter device used in the treatment of brain cancer.

GliaSite® Radiation Therapy System (RTS) is for the treatment of brain cancer, i.e. primary and recurrent gliomas and metastic brain tumors.  Specifically, the intended use of GliaSite® RTS is the management of surgically resectable brain tumors where adjuvant radiation therapy of the post-resection tissue bed is indicated.

IPSCIO Record ID: 415

License Grant
The Company acquired the intellectual property rights relating to certain combination immunogene therapy technology from Licensor, an individual.
License Property
The technology allows for making a tumor cell more recognizable by the immune system and rendering it susceptible to the cell-killing component of the immune response.

A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025.  The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the body’s immune system and destroy cancer cells.  The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF.  Our technology, which shows potential for fighting cancer by enhancing one’s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 367327

License Grant
In consideration of the equity in the Canadian Licensee, the royalty payments reserved herein, and the covenants on the part of the Licensee contained herein, the Canadian University hereby
(a)           grants to the Licensee an exclusive worldwide license to use and sublicense the Technology, any University Improvements and Confidential Information on the terms and conditions hereinafter set forth during the term of this Agreement;  and
(b)           grants to the Licensee an exclusive worldwide license to use and sublicense to manufacture, distribute, have distributed, sell and have sold, Products on the terms and conditions hereinafter set forth during the term of this Agreement.

The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any University Improvements with the prior written consent of the University, which consent shall not be unreasonably refused.

License Property
Technology relating to antisense oligonucleotide therapy for the treatment of prostate cancer and other cancers.

U.S. Provisional filed July 19, 1999 – Serial No. 60/144,495
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone–Regulated Tumors

Full U.S. application flied July 19, 2000 – Serial No. 09/619,908
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

PCT filed July 19, 2000 – Serial No. PCT/CA00/00853
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

Field of Use
Field of use is for the treatment of prostate cancer and other cancers.

OGX-011 is focused on reducing clusterin production to enhance treatment sensitivity and delay tumor progression in patients who have not fully developed treatment resistance and to restore treatment sensitivity in patients who have developed treatment resistance. Clusterin is a cell survival protein that is over-produced in several cancer indications in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration.

IPSCIO Record ID: 26749

License Grant
The University hereby grants to Licensee, under the Licensed Patents and other intellectual property rights of The University, subject to all the terms and conditions of this Agreement, a non-transferable worldwide exclusive license for the term defined by Article III to make, have made, use, sell and practice the Invention.
License Property
The University has  produced an invention entitled Novel Vectors for Gene Delivery and Therapy (OCR 722) and Specific Vectors in Gene Delivery to HIV+ Cells (OCR 721) and Vectors for the Diagnosis and Treatment of Solid Tumors Including Melanoma, U.S. Patent Application no. 08/486,422 (the INVENTION).  This invention focuses on the design of vectors for specific delivery of genes to human immunodeficiency virus (HIV)-infected cells.
Field of Use
We have recently demonstrated that certain bacterial and protozoan organisms, e.g. Salmonella typhymurium, Leishmania amazonensis, and Mycobacterium avium exhibit invasion preference for human melanoma or colon carcinoma cells over normal human melanocytes and colon epithelium in culture.  Further, mutants of Salmonella typhymurium were isolated showing enhanced specificity for melanoma and colon carcinoma cells over that already shown by the wild type parental strain.  One such superinfective, tumor-specific mutant was further transfected with a Herpes simplex thymidine kinase gene that was able to convert the non-toxic prodrug, ganciclovir, to its toxic phosphorylated form when the Salmonella was infected into melanoma tumors, thus reducing the size of the tumors. The current invention uses similar technology to isolate mutants of Salmonella typhimurium or other suitable vectors that show specific invasion preference for HIV+ cells.  Once isolated, such mutants are subjected to further genetic modifications to express and secrete suicide gene products into the cytoplasm of the HIV+ cells.  Targets for the suicide gene products include both the HIV-infected cells and/or the AIDS virus itself.

IPSCIO Record ID: 256873

License Grant
The Taiwanese Licensor hereby grants sole licensing rights to Licensee, a shareholder, in the Field and in the Territory under the Intellectual Property, Confidential Information, Data and Trademark, to develop Product.
License Property
Drug and therapeutic use of five products BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia
The new drug products that originate from Maitake Combination Therapy. The three drugs licensed from BriVision to Rgene are ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy.
Field of Use
Maitake Combination Therapy for indications including but not limited to the following breast cancer, brain tumor, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, nasopharyngeal carcinoma, prostate cancer, cervix cancer, oral/ pharynx/larynx cancer, lung cancer, leukemia, myeloma, lymphoma, gastric cancer, thyroid cancer, esophageal cancer, gastric cancer, small intestine cancer, large intestine/colon/rectal cancer, ovary cancer, skin cancer, head and neck, soft tissue sarcoma, bone tumor, bladder cancer, and cholangiocarcinomab.”

IPSCIO Record ID: 223142

License Grant
Licensor hereby grants to Licensee a royalty-bearing, exclusive right and license, with the right to sublicense as provided in this agreement, under the Licensed Patents and Know-How, to conduct research and to develop, make and have made, sell, offer to sell and have sold, import and have imported Licensed Products in the Field in the Territory; provided, however, that such license grant is subject to the restrictions set forth.
License Property
Licensed Patents
6,284,241 – Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
6,312,695 – Compounds and methods for therapy of lung cancer
6,660,838 – Compounds and methods for therapy and diagnosis of lung cancer
Field of Use
Field shall mean the field of in vitro nucleic acid-based and antibody-based cancer diagnostics.

IPSCIO Record ID: 246213

License Grant
The University grants to Licensee, the right and exclusive license in the Territory, to make, have made, use and sell the Licensed Technology in the Field and to practice under the Patent Rights in the Field for the Term.
License Property
The University is the owner by assignment from the inventors of certain Patent Rights, entitled “Cancer prevention and therapy by exclusion of soluble tumor necrosis factor'.
Field of Use
Field shall mean treatment and/or prevention of cancer.

IPSCIO Record ID: 1366

License Grant
This Royalty Agreement is for the Licensed Intellectual Property related to the GliaSite Radiation Therapy System.

The Company has the exclusive use of its intellectual property in the field of treating brain cancer related to the production of Lotrex, which is a component of the GliaSite Radiation Therapy System.

License Property
The initial royalty year began on January 1, 2012.

Lotrex is a radioactive liquid solution used in the treatment of brain cancer.

Field of Use
Lotrex is a key component in the GliaSite radiation therapy system, an approved balloon catheter used in brachytherapy treatment of brain cancer.

IPSCIO Record ID: 277862

License Grant
University granted to the Company an exclusive license to discover, develop, manufacture and sell product in the field of cancer therapy.
License Property
The Product is the utility of serological tumor marker for tumor dynamics monitoring.
Field of Use
Rights are granted for the field of cancer therapy.

IPSCIO Record ID: 279375

License Grant
The license granted by Licensor to Licensee shall be an exclusive license as to the agreed upon Field of Use, with a right to grant sublicenses, during the Term, to use, develop, make, have made, practice, import, carry out, manufacture, have manufactured, offer for sale, sell, offer for sale and/or have sold Products in the Field of Use in the Territory.
License Property
Products shall consist of any substance, device, apparatus or method covered in whole or in part by a Valid Claim useful to the diagnosis or treatment of disease or disorders utilizing a dendritic cell based vaccine for brain tumors and other cancers.
Field of Use
Field of Use is certain provisional patents and other proprietary intellectual property, relating to the work of Dr. John Yu with cellular therapies or diagnostics utilizing cellular therapies, including dendritic cell based vaccines for brain tumors and other cancers.  License is for a cancer vaccine therapy.

IPSCIO Record ID: 28831

License Grant
Upon execution of the transfer agreement, all significant terms of the license agreement were terminated except the provision for royalties on future sales.
License Property
In consideration of the asset transfer, we agreed to assume all of Intracel’s obligations to Organon and agreed to enter into a stock exchange agreement with Intracel.
Field of Use
OncoVAX® is a cancer vaccine for the post-surgical treatment of Stage II colon cancer. OncoVAX® is an active specific immunotherapy that uses the patient’s own cancer cells to block the return of colon cancer following surgery.

IPSCIO Record ID: 371879

License Grant
Licensor in-licensed to Licensee the exclusive worldwide rights to the central nervous system (“CNS”) and/or cerebrocardiovascular drug application, including the (preventive) treatment of peripheral effects of agents causing CNS disease or symptoms, including cancer, for 2X-111.
License Property
2X-111 is an advanced, targeted liposomal formulation of Doxorubicin, one of the world’s most widely used chemotherapies. The specific 2X-111 formulation, which exploits a glutathione enhanced PEG-liposomal delivery system, may allow 2X-111 to cross the blood-brain barrier (BBB), thereby potentially enabling the treatment of primary brain tumors, such as glioblastoma multiforme (GBM), and secondary brain tumors that originated from cancers outside the brain, such as metastatic breast cancer.

Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, which is necessary for DNA replication. Topo isomerase 2 is an enzyme that cuts both strands of the DNA helix simultaneously in order to manage DNA tangles and supercoils.

Preclinical studies have been performed in order to determine the anti-cancer activity and toleration of 2X-111 both systemically and in the CNS prior to the start of the human clinical trials.

Field of Use
Field of use is for treatment of peripheral effects of agents causing CNS (central nervous system) disease or symptoms, including Cancer.

The right is  to the central nervous system (“CNS”) and/or cerebrocardiovascular drug application, including the (preventive) treatment of peripheral effects of agents causing CNS disease or symptoms, including cancer, for 2X-111

The central nervous system (CNS) is the part of the nervous system consisting primarily of the brain and spinal cord.

Cerebrovascular disease refers to a group of conditions, diseases, and disorders that affect the blood vessels and blood supply to the brain. If a blockage, malformation, or hemorrhage prevents the brain cells from getting enough oxygen, brain damage can result.

Licensee believes may allow 2X-111 to cross the blood-brain barrier (BBB), thereby potentially enabling the treatment of primary brain tumors, such as glioblastoma multiforme (GBM), and secondary brain tumors that originated from cancers outside the brain, such as metastatic breast cancer.

IPSCIO Record ID: 256273

License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use
The Field means the treatment of human diseases, disorders and conditions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.